Evidence map›Paper›PMID 25553892›Full record

ArticleBioorganic & medicinal chemistry letters2015

Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.

Juhienah K Khalaf, William S Bowen, Hélène G Bazin, Kendal T Ryter, Mark T Livesay, Jon R Ward, Jay T Evans, David A Johnson

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Juhienah K KhalafGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
William S BowenInstitute for Cellular Therapeutics, University of Louisville School of Medicine, Donald E. Baxter Biomedical Research Building, 570 South Preston Street, Louisville, KY 40202, USA.
Hélène G BazinGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
Kendal T RyterGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
Mark T LivesayGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
Jon R WardGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
Jay T EvansGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
David A JohnsonGlaxoSmithKline Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA. Electronic address: david.a.johnson@gsk.com.
GlaxoSmithKline (United States) · USUniversity of Louisville · US

Funding

NIAID NIH HHS HHSN272200900008CNIAID NIH HHS N01 AI040008
6 · The paper itself

Abstract

TLR4 agonists that favor TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.

Indexed as

Adaptor Proteins, Vesicular TransportBinding SitesBiocompatible MaterialsCytokinesGlucosamineHEK293 CellsHumansLipid AMolecular Docking SimulationMyeloid Differentiation Factor 88NF-kappa BOrganophosphorus CompoundsProtein BindingProtein Structure, TertiarySignal TransductionToll-Like Receptor 4Adaptor Proteins, Vesicular TransportAGP 527Biocompatible MaterialsCytokinesGlucosamineLipid AMyeloid Differentiation Factor 88NF-kappa BOrganophosphorus CompoundsTICAM1 protein, humanToll-Like Receptor 4AGPGlycolipidsLipid A mimeticNF-κB activityTLR4 agonistTRIF selectivityVaccine adjuvant

Identifiers

PMID25553892
PMCPMC4330088
OpenAlexW1989870133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.